Warner Chilcott Falls On Litigation News

Warner Chilcott's term loan "B" dropped under par on news it is being sued by the U.S. Federal Trade Commission for blocking generic production of an oral contraceptive.

  • 11 Nov 2005
Email a colleague
Request a PDF

Warner Chilcott's term loan "B" dropped under par on news it is being sued by the U.S. Federal Trade Commission for blocking generic production of an oral contraceptive. Its term loan "B" fell to 99 7/8 from 100 1/8. Warner Chilcott, a pharmaceutical company, reportedly paid another drug company, Barr Pharacueticals, $20 million to prevent Barr's generic Ovcon from entering the U.S. market until May 2009. The suit filed in the U.S. District Court for the District of Columbia seeks to stop the provision barring the generic version from the U.S. market. Twenty-one states and the District of Columbia are reportedly seeking civil penalties. Warner Chilcott officials could not be reached by press time.

  • 11 Nov 2005

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 Citi 4,347 16 16.63
2 BNP Paribas 2,866 11 10.96
3 Morgan Stanley 2,420 6 9.26
4 Goldman Sachs 2,276 6 8.71
5 Bank of America Merrill Lynch (BAML) 2,086 9 7.98

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 58,873.50 192 10.79%
2 JPMorgan 51,400.14 152 9.42%
3 Bank of America Merrill Lynch 41,109.55 134 7.53%
4 Wells Fargo Securities 40,627.46 119 7.45%
5 Credit Suisse 38,293.55 120 7.02%